| 1 |
35165100 | Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma. | 2022 Apr 14 |
1 |
| 2 |
33170322 | An investigation into possible interactions among four vascular epidermal growth factor receptor-tyrosine kinase inhibitors with gefitinib. | 2021 Jan |
1 |
| 3 |
31035254 | EGF and IGF1 affect sunitinib activity in BP-NEN: new putative targets beyond VEGFR? | 2019 Jun 1 |
1 |
| 4 |
31054432 | Exploration of N-alkyl-2-[(4-oxo-3-(4-sulfamoylphenyl)-3,4-dihydroquinazolin-2-yl)thio]acetamide derivatives as anticancer and radiosensitizing agents. | 2019 Jul |
1 |
| 5 |
28327411 | Gas6-Axl signaling in presence of Sunitinib is enhanced, diversified and sustained in renal tumor cells, resulting in tumor-progressive advantages. | 2017 Jun 1 |
1 |
| 6 |
26934000 | The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling. | 2016 Apr 12 |
1 |
| 7 |
27016208 | Schedule-dependent cytotoxicity of sunitinib and TRAIL in human non-small cell lung cancer cells with or without EGFR and KRAS mutations. | 2016 Aug |
1 |
| 8 |
27149458 | Recurrent Olfactory Neuroblastoma Treated With Cetuximab and Sunitinib: A Case Report. | 2016 May |
1 |
| 9 |
27706901 | Targeting a Targeted Drug: An Approach Toward Hypoxia-Activatable Tyrosine Kinase Inhibitor Prodrugs. | 2016 Nov 7 |
2 |
| 10 |
25971960 | Receptor Tyrosine Kinase Expression Predicts Response to Sunitinib in Breast Cancer. | 2015 Dec |
1 |
| 11 |
26306766 | Induction of epithelial-mesenchymal transition via activation of epidermal growth factor receptor contributes to sunitinib resistance in human renal cell carcinoma cell lines. | 2015 Nov |
9 |
| 12 |
26484875 | Inhibition of epithelial growth factor receptor can play an important role in reducing cell growth and survival in adrenocortical tumors. | 2015 Dec 15 |
3 |
| 13 |
24118906 | The evaluation of efficacy and safety of sunitinib on EGFR-TKI pretreated advanced non-small cell lung cancer patients in China. | 2014 Apr |
1 |
| 14 |
25085632 | Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial. | 2014 Aug 1 |
1 |
| 15 |
22819259 | Blockade of NFκB activity by Sunitinib increases cell death in Bortezomib-treated endometrial carcinoma cells. | 2012 Oct |
1 |
| 16 |
23056179 | Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy. | 2012 |
1 |
| 17 |
20524040 | Sunitinib induces PTEN expression and inhibits PDGFR signaling and migration of medulloblastoma cells. | 2011 Jan |
1 |
| 18 |
21796416 | Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation. | 2011 Sep |
2 |
| 19 |
20558072 | Design, synthesis and evaluation of 2-amino-4-m-bromoanilino-6-arylmethyl-7H-pyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors and antiangiogenic agents. | 2010 Jul 15 |
1 |
| 20 |
21187479 | The effects of anti-VEGFR and anti-EGFR agents on glioma cell migration through implication of growth factors with integrins. | 2010 Dec |
2 |
| 21 |
16046538 | Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. | 2005 Aug 2 |
2 |